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Abstract 
Due to the number of acetaminophen overdoses each year, 
the Food and Drug Administration and the National Center 
for Prescription Drug Programs made changes and 
recommendations regarding the labeling of acetaminophen-
containing products. It is important for pharmacists to 
understand these changes and to educate patients on the 
correct use of these products. 
Introduction 
Acetaminophen is one of the most commonly used medica-
tions in the United States. A 2006 survey showed that during 
any given week, 19 percent of adults and 11 percent of chil-
dren were using acetaminophen-containing products.1 If 
taken in excess, acetaminophen can cause liver injury. The 
Food and Drug Administration (FDA) estimates that 14 to 21 
percent of all acetaminophen overdoses are not intended; 
however, some patients may intentionally overdose on 
acetaminophen.z Since the 1990s, efforts have been made to 
decrease the number of acetaminophen-related liver 
injuries, but medical literature continues to show that 
acetaminophen-related liver injuries are still a serious public 
health problem.3 Recently the FDA and the National Center 
for Prescription Drug Programs (NCPDP) have taken actions 
to help mitigate this problem. Labeling of prescription 
products containing acetaminophen will be changing, and 
suggestions for the labeling of over the counter (OTC) 
products were proposed as well. With the new labeling 
changes to come out within the next few years, pharmacists 
can help play a role in overdose prevention by providing 
patient counseling and education. 
Background 
In the years 1998-2003, acetaminophen-related liver injury 
was the leading cause of acute liver failure in the United 
States.4 Acetaminophen does not harm the liver directly; in-
stead the harm is caused by one of its metabolites.s A small 
percentage of acetaminophen is excreted unchanged in the 
urine, but the remaining amount is metabolized in the liver. 
In adults, approximately 75 percent of acetaminophen is bro-
ken down by the liver into inactive metabolites. The rest is 
metabolized by CYP2E1 to form N-acetyl-parabenzoqui-
noneimine (NAPQI). Normally the body rids itself of NAPQI 
by binding it with glutathione and excreting it. During an 
overdose, the production of NAPQI exceeds the supply of 
glutathione causing a toxic buildup of NAPQI. Patients with a 
history of chronic alcohol use, binge drinking, or liver disease 
may be more prone to liver injury from acetaminophen 
because of increased production of toxic metabolites or 
decreased clearance of the metabolites.3,6 
Symptoms of acetaminophen overdose vary.s Some patients 
appear asymptomatic while others experience GI symptoms 
or pain in the upper right quadrant. Initial signs of hepatic 
failure such as metabolic acidosis start to occur within 24 to 
72 hours of overdose. 
Acetaminophen overdose is diagnosed by patient history and 
current acetaminophen levels.6 The antidote of choice is 
N-acetylcysteine.s N-acetylcysteine is most effective when 
administered no more than 8-10 hours after ingestion of 
acetaminophen, but may be effective if started within 24 
hours.s.6 Treatment is continued until either the patient 
shows clinical and laboratory improvement, the patient 
receives a liver transplant, or death occurs. Mortality associ-
ated with acetaminophen-related acute liver failure is nearly 
30 percent and is often due to cerebral edema. If the patient 
survives, the liver will typically return to baseline function 
within three months.6 
Prescription Label Changes 
On January 13, 2011, the FDA released information regarding 
changes of acetaminophen in prescription combination prod-
ucts. The main focus of the changes included limiting the 
amount of acetaminophen to no more than 325 mg in each 
tablet or capsule.7 Many acetaminophen overdoses are unin-
tentional and are due to the patient's lack of knowledge 
about products containing acetaminophen. The FDA hopes to 
prevent these unintentional overdoses by limiting the 
amount of acetaminophen in prescription products.3 Further-
more, the FDA also requires an update on the labels of pre-
scription combination acetaminophen products.7 Manufac-
turers will need to include a boxed warning on the label 
about the potential risk for severe liver injury and a warning 
regarding the potential for allergic reactions.a There will be a 
three-year period for all manufacturers to re-formulate their 
products to adhere to these new regulations, with a deadline 
in 2014. For a list of prescription drugs that are affected, re-
fer to the following website: http://www.fda.gov/Drugs/ 
DrugSafety /ucm239821.htm .9 
The NCPDP developed a work group to help form standard 
best practices and suggestions for prescription labels of 
products containing acetaminophen. The NCPDP work group 
developed recommendations to improve labels by creating 
similarities between OTC and prescription labels. Their goal 
is to decrease patient misinterpretation of the label, which 
may reduce the occurrence of acetaminophen overdose. 
Table 1 shows recommendations made by NCPDP.lO 
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OTC Label Changes 
At the time of this writing, the FDA's decision did not affect 
OTC products, although in May 2011 the FDA Advisory Panel 
for Nonprescription Medications released recommendations 
for OTC medications (Table 2). 
OTC products containing acetaminophen are not officially 
affected by the FDA's decision, but McNeil Consumer Health-
care (the manufacturer of Tylenol®) announced changes to 
their products in response to the new recommendations that 
are expected to occur in 2012. A new maximum daily dose 
will be provided for regular strength and extra strength for-
mulations. McNeil Consumer Healthcare also plans on chang-
ing their liquid formulations to make one consistent liquid 
dose for both children's and infant's Tylenol®. Furthermore, 
dosing instructions will be based on age and weight and will 
be provided for children as young as six months of age. The 
manufacturer hopes these changes will help eliminate medi-
cation errors and decrease the chance of accidental aceta-
minophen overdoses.11 
The NCPDP suggests that OTC labeling should change as well 
to help patients avoid acetaminophen overdoses. Suggested 
label changes include highlighting "acetaminophen" under 
the active ingredients portion and adding more caution ele-
ments to the warning section.10 
Pharmacist Involvement 
As members of the FDA met to discuss acetaminophen, they 
focused on a quote from Paracelsus, "Everything is a poison. 
What differentiates a poison from a remedy is the dose."12 
This quote stresses the importance of the pharmacist's role 
in educating patients and caregivers about proper dosing and 
use of acetaminophen-containing products (Tables 3 and 4). 
A government study found that almost 89 million American 
adults of various age, race, and economic status suffer from 
low health literacy, which refers to ability to make health 
decisions and follow treatment instructions. Given the large 
number of individuals with low health literacy, it is impor-
tant for pharmacists to appropriately counsel all patients and 
caregivers. This would help minimize the likelihood of nega-
tive outcomes such as more serious medical problems, in-
creased medical costs, and more doctor and hospital visits.13 
Table 1. NCPDP Recommendations for Prescription 
Labeling1° 
• Complete spelling of active ingredients in 
acetaminophen- containing drugs (avoid use of 
the abbreviation "APAP") 
• Standard acetaminophen use and 
liver damage warning label 
• Prioritize the warning label on packaging 
• Acetaminophen warning icon on product 
to ensure patient awareness 
• Use plain language principles and patient-centered 
labels to increase patient comprehension 
Table 2. Suggestions made by the FDA Advisory Panel 
for Nonprescription Medications11 
• One strength ofliquid, chewable, and tablet form 
(currently there are 7 different strengths) 
• Children's dosing instruction begin at 6 months 
• Dosing based on weight, not just age 
• Dosing device standards on spoons and cups 
with a consistent unit for measuring 
(current units include mL, cc, and tsp) 
Table 3. Counseling Points For Adult Patients Using 
Acetaminophen-containing Products1s 
• Do not exceed 4 grams/day 
• Do not take multiple acetaminophen-containing 
products 
• Do not drink alcohol while taking acetaminophen-
containing products 
• Use has caused severe liver injury and cases of 
hypersensitivity reactions 
• Report anytime more was taken than directed 
• Report adverse events 
Table 4. Counseling Points for Advising Parents or 
Other Caregivers on Acetaminophen Use in Children 
• Do not give multiple medications containing 
acetaminophen.16 
• Give only as long as necessary; check with the health 
care provider if the child needs medication for more 
than a few days.16 
• Since labels are at an 8th grade reading ability (and 
almost half of American adults read below this level), 
explain the label and how to calculate and measure 
doses.17 
0 Explain: 
• appropriate use of measuring devices 
• how to measure correct amount 
• dosing schedule16 
• Contact doctor ifthe infant or child is lethargic or 
difficult to wake up.16 
• Use weight-based dosing; not to exceed 5 doses per 
day. 17 
• There are different concentrations in various 
preparations.17 
0 Given the anticipated changes to the OTC 
products, always confirm the formulation 
of the product being used; do not assume 
the caregiver has the most current product.a 
• Use a single liquid preparation for all infants and 
children in a household.17 
• Fevers are protective mechanisms and do not always 
need treated.17 
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A study surveying patients' knowledge related to acetamino-
phen recognition, dosing, and toxicity showed the need for 
proper counseling by a healthcare provider. Patients (n=284) 
19 years or older were questioned about current and/ or re-
cent use of pain, cold, or allergy medications. Out of patients 
reporting use, only 25 percent knew the active ingredient. 
Less than half of the patients knew that Tylenol® and aceta-
minophen were synonymous and even fewer knew that 
APAP was also an alternative name. Only 13 percent of pa-
tients correctly identified three labels as containing Tylenol®. 
Although the majority of patients knew the potential harm of 
Tylenol®, some thought taking a harmful amount was diffi-
cult or impossible. Few patients knew the correct dose and 
many patients chose doses at toxic levels.14 This study 
showed that without appropriate knowledge on terminology, 
toxicity, and dosing of acetaminophen, the potential for harm 
exists. Counseling and patient education, along with the re-
cently announced changes to strength and labeling of prod-
ucts, are key to reducing the incidence of acetaminophen 
overdose. 
Multiple studies have shown that acetaminophen overdose 
affects children as well. Children do not reach adult levels of 
hepatic metabolism and excretion until they are about 12 
years old. 16 There have been a few reports of toxicity at 
doses of 50-75 mg/kg/day.16 
Studies have found that overdoses occurred when teaspoon-
ful quantities of infant drops were given instead of the chil-
dren's liquid formulation and when regular strength tablets 
were given instead of children's chewable tablets.17 In addi-
tion, another study was performed to assess the impact of 
dosing instruments and parents' ability to correctly use 
them. It was observed that parents (n=302) were more likely 
to make dosing errors when using a dosing cup compared to 
other dosing forms due to confusion of teaspoon versus ta-
blespoon instructions, assumptions that the full cup indi-
cated the unit dose, and lack of eye-level dose verifications.18 
Data has shown that there are high rates of errors in dosing 
infant acetaminophen, even among parents with adequate 
health literacy; a pictogram may be beneficial to educate pa-
tients on proper dosing.19 
For these reasons, caregivers should be informed about 
proper dosing and accurate use of dosing instruments. 10 Par-
ents may consult the pediatrician if the child seems nause-
ated, vomits, and/or becomes lethargic after consuming 
these products. However, by that time, liver injury may have 
already occurred.17 Therefore, it is important for caregivers 
to know the instructions for dosing and signs of potential 
toxicity. 
Medicines in My Home (MIMH) is an interactive program 
created by the FDA to teach consumers how to properly 
choose and use OTC medications. Pharmacists can utilize 
these resources or refer their patients to the website: http:// 
www.fda.gov/Drugs/ResourcesForYou/Consumers/ Buying 
UsingMedicineSafely /UnderstandingOver-the-CounterMedicines / 
ucm092139.htm. 
Conclusion 
Based on the information known about acetaminophen asso-
ciated hepatotoxicity due to overdose and the FDA's recent 
actions regarding acetaminophen labeling, pharmacists 
should educate patients and caregivers on these changes and 
counsel them on proper use and dosing of acetaminophen-
containing products. 
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